AFP DEPARTMENT COLLECTION
This department includes information about new drugs from the perspective of the five attributes to be considered when weighing the advantages of one drug over another: Safety, Tolerability, Effectiveness, Price, and Simplicity.
Apr 15, 2021 Issue
Elagolix, Estradiol, and Norethindrone Kit (Oriahnn) for the Management of Heavy Menstrual Bleeding Associated with Fibroids
Oriahnn can decrease menstrual blood loss in premenopausal patients with uterine fibroids. Although it has been studied for only six months of use and may result in significant bone loss, it is labeled for up to two years of continuous therapy.
Mar 15, 2021 Issue
Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia
Bempedoic acid is labeled as add-on therapy to diet and maximally tolerated statin for the treatment of familial hypercholesterolemia or atherosclerotic cardiovascular disease.
Feb 15, 2021 Issue
Lemborexant (Dayvigo) for the Treatment of Insomnia
Lemborexant (Davigo) is labeled for adults with insomnia to improve with sleep onset and maintenance.
Jan 15, 2021 Issue
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke
Icosapent ethyl is safe, well tolerated and effective in preventing ischemic events including stroke and heart attack.
Dec 15, 2020 Issue
Lasmiditan (Reyvow) for the Treatment of Acute Migraine
Lasmiditan is a costly alternative to other more extensively studied medications for acute migraine. It should be reserved for those patients who lack relief with other available agents or who cannot tolerate other abortive medications.
Nov 15, 2020 Issue
Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus
Oral semaglutide (Rybelsus) is labeled as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Oct 15, 2020 Issue
Trifarotene (Aklief) for the Treatment of Acne
Trifarotene is a monotherapy option for acne affecting the face and trunk and offers an alternative to topical antibiotics or anti-inflammatory agents for the management of moderate inflammatory and noninflammatory acne.
Sep 15, 2020 Issue
Lefamulin (Xenleta) for the Treatment of Community-Acquired Bacterial Pneumonia
Lefamulin may be considered for patients hospitalized with community-acquired bacterial pneumonia.
Aug 15, 2020 Issue
Sarecycline (Seysara) for the Treatment of Acne
Sarecycline is a once-daily oral medication for patients with moderate to severe non-nodular acne. Its benefit over less expensive options has not been demonstrated.
Jul 15, 2020 Issue
Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure
Dapagliflozin can be added to existing treatment to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes who have established CVD or are at high risk of CVD. It may also decrease the risk of renal disease progression and death from renal failure.